Pharmacogenomics of anthracycline-induced cardiotoxicity in children with cancer

Pharmacogenomics of anthracycline-induced cardiotoxicity in children with cancer - Pharmacogenomics and anthracycline cardiotoxicity

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33355

Enrollment

Registered

2009-04-14

Start date

2009-03-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart damage cardiotoxicity

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Diagnosis of childhood cancer and treatment with anthracyclines Decreased heart function and normal heart function Age: at least 18 years old

Exclusion criteria

Exclusion criteria: Age: below 18 years

Design outcomes

Primary

Measure	Time frame
gene variants responsible for anthracycline-induced	—

Secondary

Measure	Time frame
nvt	—

Countries

Netherlands

Outcome results